Sunday, July 6, 2025 7/6/2025

Optimization of aminolevulinic acid-protoporphyrin IX for fluorescence-guided tumor resection and treatment

Award Number: R15CA268200
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2022
PERIOD OF PERFORMANCE END DATE: 12/31/2025

Group Awards By:

View Award Description

Optimization of aminolevulinic acid-protoporphyrin IX for fluorescence-guided tumor resection and treatment - NCI Diversity Supplement Application Parent grant: Optimization of aminolevulinic acid-protoporphyrin IX for fluorescence-guided tumor resection and treatment (R15CA268200-02, PI: Bin Chen) This diversity supplement application is to support Ms. Jordyn Olsen, a first-generation college graduate in her family, to pursue PhD training in cancer research with the goal of promoting women and minorities in cancer research workforce. Aminolevulinic acid (ALA) is one of a few FDA-approved intraoperative fluorescent probes and the only molecular probe based on the metabolic alterations in tumor cells. ALA has no fluorescence on its own and needs to be metabolized in the heme biosynthesis pathway in tumor cells to produce a fluorescent and photosensitizing metabolite protoporphyrin IX (PpIX), which enables tumor fluorescence imaging for tumor detection and photodynamic therapy (PDT) for cancer treatment. Although ALA-PpIX has been clinically used for fluorescence-guided tumor resection and cancer treatment, its applications are limited by low tumor PpIX fluorescence, high tumor fluorescence heterogeneity, and low tumor-to-normal tissue fluorescence contrast. Research supported by the parent grant has led to the identification of ABCG2 transporter activity as a critical factor in reducing tumor PpIX fluorescence. More importantly, we have identified clinically used agents to suppress ABCG2 activity to enhance tumor PpIX fluorescence. In this supplement research, Jordyn will determine whether variation in ABCG2 expression results in intra-tumor and inter-tumor heterogeneity in ALA- PpIX fluorescence. In addition, she will investigate whether PpIX fluorescence heterogeneity in tumor cells can be suppressed by ABCG2 inhibition. This proposed research is related to the on-going work supported by the parent grant funding and will further expand scope of parent grant research. Support from this supplement funding will enable Jordyn to complete the necessary training in cancer research so that she will have the knowledge and skills to start her career as a cancer researcher.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $146,832 )
2023	2023	SAINT JOSEPHS UNIVERSITY	5600 CITY AVE	PHILADELPHIA	PA	19131	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	007	3	9/15/2023	SUPPLEMENT FOR EXPANSION	$118,970
2023	2022	SAINT JOSEPHS UNIVERSITY	5600 CITY AVE	PHILADELPHIA	PA	19131	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	006	3	7/10/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$20,487
2023	2022	UNIVERSITY OF THE SCIENCES IN PHILADELPHIA	600 S 43RD ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	004	2	5/12/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$20,487
2023	2022	SAINT JOSEPHS UNIVERSITY	5600 CITY AVE	PHILADELPHIA	PA	19131	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	003	3	3/21/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$5,732
2023	2022	UNIVERSITY OF THE SCIENCES IN PHILADELPHIA	600 S 43RD ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	005	2	7/10/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$20,487
2023	2022	ST JOSEPH'S UNIVERSITY	5600 CITY AVE	PHILADELPHIA	PA	19131	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	001	3	1/25/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$427,750
2023	2022	UNIVERSITY OF THE SCIENCES IN PHILADELPHIA	600 S 43RD ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	000	2	1/25/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$420,375
2023	2022	UNIVERSITY OF THE SCIENCES IN PHILADELPHIA	600 S 43RD ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	002	2	3/21/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$5,732
														Subtotal = $146,832

Issue Date FY: 2022 ( Subtotal = $427,500 )
2022	2022	UNIVERSITY OF THE SCIENCES IN PHILADELPHIA	600 S 43RD ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	001	2	1/7/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2022	2022	UNIVERSITY OF THE SCIENCES IN PHILADELPHIA	600 S 43RD ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Detection and Diagnosis Research	000	2	12/20/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$427,500
														Subtotal = $427,500

Grand Total All Awards = $574,332

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Optimization of aminolevulinic acid-protoporphyrin IX for fluorescence-guided tumor resection and treatment

Award Number: R15CA268200

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2022

PERIOD OF PERFORMANCE END DATE: 12/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer